Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27574562)

Published in World J Gastrointest Pathophysiol on August 15, 2016

Authors

Pavan Patel1, Steven E Schutzer1, Nikolaos Pyrsopoulos1

Author Affiliations

1: Pavan Patel, Steven E Schutzer, Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ 07101-1709, United States.

Associated clinical trials:

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | NCT01839604

to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) (MG4101) | NCT02008929

Articles citing this

Immunoregulatory Role of NK Cells in Tissue Inflammation and Regeneration. Front Immunol (2017) 0.75

Articles cited by this

(truncated to the top 100)

The hallmarks of cancer. Cell (2000) 113.05

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Inflammation and cancer. Nature (2002) 53.78

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Pathogen recognition and innate immunity. Cell (2006) 44.14

Cancer-related inflammation. Nature (2008) 34.21

Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57

Immunity, inflammation, and cancer. Cell (2010) 28.27

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17

Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81

Hepatocellular carcinoma. N Engl J Med (2011) 19.40

Regulatory T cells and immune tolerance. Cell (2008) 18.77

Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31

Hepatocellular carcinoma. Lancet (2012) 18.09

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62

Interleukin-17 family members and inflammation. Immunity (2004) 16.16

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82

Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76

NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14

Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55

Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44

The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91

Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85

Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28

HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12

Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78

FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 8.73

STATs in oncogenesis. Oncogene (2000) 8.60

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54

Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61

Human natural killer cells. Blood (2008) 7.37

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07

Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 6.96

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J (2000) 6.55

CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42

The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 6.42

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 5.97

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28

AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A (1998) 4.99

Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90

Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (2015) 4.37

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95

The oncogenic activation of beta-catenin. Curr Opin Genet Dev (1999) 3.87

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34

Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology (2004) 3.30

Liver: An organ with predominant innate immunity. Hepatology (2008) 3.13

STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol (2003) 3.04

Signal transduction of beta-catenin. Curr Opin Cell Biol (1995) 2.96

Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 2.84

PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell (1998) 2.83

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 2.73

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63

Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev (2010) 2.61

Th17 T cells: linking innate and adaptive immunity. Semin Immunol (2007) 2.54

Insights into antiparallel microtubule crosslinking by PRC1, a conserved nonmotor microtubule binding protein. Cell (2010) 2.50

Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26

Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23

The β-catenin destruction complex. Cold Spring Harb Perspect Biol (2013) 2.22

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res (2007) 2.21

TCF/LEF factor earn their wings. Trends Genet (1997) 2.19

mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14

Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11

New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05

Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01

Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res (2004) 2.01

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology (1998) 1.97

Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest (2010) 1.96